Internal Medicine, Medical Oncology · San Antonio, TX
NPI
1841235439
Since 2006
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
7979 Wurzbach Rd Fl Z5
San Antonio, TX, 78229
Phone (210) 450-2872
Groups this clinician bills Medicare through
Medicare paid, 2024
$985K
39,522 services
Medicare patients, 2024
327
Average age 73
Drug cost, 2024
$3.4M
1,451 prescriptions
Company payments, 2025
$90K
From 15 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Virginia Kaklamani was code J9271 (injection, pembrolizumab, 1 mg), 7,200 times for 17 patients. In total Virginia Kaklamani billed 39,522 services in 112 codes, and Medicare paid $985K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2015-02-11.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J9271 Injection, pembrolizumab, 1 mg | Office | 7,200 | 17 | $44.89 | $323K |
| J1453 Injection, fosaprepitant, 1 mg | Office | 3,300 | 15 | $0.10 | $345 |
| J9030 Bcg live intravesical instillation, 1 mg | Office | 1,501 | 22 | $2.09 | $3,136 |
| J9171 Injection, docetaxel, 1 mg | Office | 1,140 | 13 | $0.61 | $697 |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 544 | 27 | $0.09 | $48.03 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 312 | 161 | $12.50 | $3,901 |
| J2405 Injection, ondansetron hydrochloride, per 1 mg | Office | 308 | 16 | $0.07 | $22.43 |
| 99214 Office E&M - Established | Office | 304 | 147 | $94.02 | $29K |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 241 | 18 | $0.64 | $155 |
| J9201 Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | Office | 233 | 25 | $2.35 | $549 |
| 96413 Chemotherapy Administration | Office | 103 | 62 | $92.97 | $9,576 |
| 96375 Injection Administration | Office | 102 | 37 | $12.31 | $1,256 |
| 96367 Intravenous Infusion, Hydration | Office | 78 | 33 | $22.76 | $1,775 |
| 99215 Office E&M - Established | Office | 53 | 39 | $138.17 | $7,323 |
| 51720 Chemotherapy Administration | Office | 53 | 35 | $65.09 | $3,450 |
By year: 2022 $1.4M for 60,184 services; 2023 $772K for 39,613 services; 2024 $985K for 39,522 services.
Medicare prescription drug claims, 2024
In 2024, the drug Virginia Kaklamani prescribed most often to Medicare patients was Anastrozole, with 463 prescriptions and refills. In total Virginia Kaklamani wrote 1,451 Medicare prescriptions that cost $3.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 463 | 1,176 | 141 | $8,119 |
| Alendronate Sodium Generic | 105 | 237 | 35 | $928 |
| Letrozole Generic | 82 | 198 | 26 | $1,772 |
| Kisqali Ribociclib Succinate | 63 | 63 | 11 | $1.1M |
| Ibrance Palbociclib | 62 | 62 | Under 11 | $957K |
| Exemestane Generic | 56 | 152 | 21 | $10K |
| Prochlorperazine Maleate Generic | 55 | 55 | 17 | $977 |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 48 | 48 | 16 | $1,366 |
| Tamoxifen Citrate Generic | 29 | 71 | Under 11 | $633 |
| Gabapentin Generic | 29 | 64 | 12 | $468 |
| Dexamethasone Generic | 26 | 26 | 13 | $286 |
| Morphine Sulfate Er Morphine Sulfate | 24 | 24 | Under 11 | $755 |
| Ondansetron Hcl Generic | 20 | 20 | 17 | $468 |
| Ondansetron Odt Ondansetron | 20 | 20 | Under 11 | $190 |
| Olanzapine Generic | 17 | 18 | Under 11 | $75.54 |
Brand drugs: - claims; generic drugs: 1,227 claims; opioid claims: 90.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Virginia Kaklamani $90K ($90K in general payments such as food, travel and fees and $223 for research) from 15 companies. The largest payer was Gilead Sciences, Inc. with $50K.
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. GILD | 30 | $50K |
| AstraZeneca Pharmaceuticals LP AZN | 13 | $12K |
| Stemline Therapeutics Inc. | 6 | $11K |
| Daiichi Sankyo Inc. 4568.T | 7 | $6,077 |
| Lilly USA, LLC LLY | 1 | $4,400 |
| Merck Sharp & Dohme LLC MRK | 6 | $2,539 |
| Genentech USA, Inc. ROG.SW | 1 | $2,050 |
| Novartis Pharmaceuticals Corporation NVS | 2 | $1,623 |
| Eli Lilly and Company LLY | 1 | $800 |
| Pfizer Inc. PFE | 2 | $85.28 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.